Houston, Feb. 5, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the treatment of short bowel syndrome (SBS).

Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.

Houston, July 31, 2018 – Pharm-Olam International, a global, full-service contract research organization (CRO) specializing in oncology, infectious diseases and vaccines, rare and orphan diseases, provides multiple resources for life science organizations to comply with the new European Union General Data Protection Regulation (GDPR). Pharm-Olam provides education and consultation on how the GDPR affects clinical trial conduct and also works directly with companies to achieve compliance.

HOUSTON, Tx. — April 26, 2018. Pharm-Olam International, a global, full-service Contract Research Organization (CRO) specializing in Oncology, Infectious Diseases & Vaccines, Rare Diseases and Pediatric indications, is prepared for the implementation of the European Union’s (EU’s) General Data Protection Regulation (GDPR), which will impact our industry among others where organizations collect and hold personal data on EU citizens.  Utilizing Pharm-Olam’s version of the Bow Tie Methodology for visual risk assessment and management, powered by Ideagen’s Q-Pulse software, Pharm-Olam is fully prepared for the global GDPR roll-out. In anticipation of GDPR’s effective date (May 25, 2018), Pharm-Olam will be hosting an interactive 60-minute live training webinar on May 15, 2018 at 11a.m. EST for its pharmaceutical and biotechnology partners and clients.  Registration and attendance is open to the public.  

Pharm-Olam International, a multinational, full-service Clinical Research Organization (CRO) specializing in Oncology, Infectious Diseases, Rare Diseases and Pediatric indications, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H. as Chief Medical Officer (CMO).

HOUSTON, TX – Pharm-Olam International LLC, an award-winning, multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the company has been selected as a winner in Life Science Leader magazine’s 2017 CRO Leadership Awards.

HOUSTON, TX – Pharm-Olam International LLC, a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of John Barry as Chief Operating Officer.

Global clinical research experts Yamin “Mo” Khan, PhD, and Dhiraj Abhyankar, MD will host an interactive discussion and seminar on the Evolution of Response Evaluation in Oncology Trials. The free public forum will be held at 11 a.m. Eastern Standard Time on Thursday, March 30 via webinar.